[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100557103":3},{"organization":4,"armGroups":7,"interventions":18,"overallOfficials":11,"centralContacts":26,"locations":32,"responsibleParty":215,"collaborators":11,"id":217,"slug":11,"hasResults":218,"nctId":219,"briefTitle":220,"officialTitle":221,"acronym":11,"eligibilityCriteria":222,"healthyVolunteers":218,"sex":223,"minAge":224,"maxAge":11,"enrollmentInfo":225,"targetDuration":11,"studyType":228,"phases":229,"briefSummary":231,"conditions":232,"keywords":11,"overallStatus":35,"whyStopped":11,"lastUpdateSubmitDate":235,"lastUpdatePostDateStruct":236,"startDateStruct":239,"completionDateStruct":241,"leadSponsor":243,"locationsCount":244},{"fullName":5,"class":6},"Stelexis BioSciences","INDUSTRY",[8,14],{"label":9,"type":10,"description":11,"interventionNames":12},"Eganelisib","EXPERIMENTAL",null,[13],"Drug: Eganelisib",{"label":15,"type":10,"description":11,"interventionNames":16},"Eganelisib in combination with cytarabine",[17],"Drug: Eganelisib in combination with cytarabine",[19,23],{"type":20,"name":9,"description":21,"armGroupLabels":22,"otherNames":11},"DRUG","eganelisib will be administered as monotherapy",[9],{"type":20,"name":15,"description":24,"armGroupLabels":25,"otherNames":11},"eganelisib will be administered in combination with cytarabine",[15],[27],{"name":28,"role":29,"phone":30,"phoneExt":11,"email":31},"Clinical Trials Office Stelexis","CONTACT","508-543-6979","clinicaltrials@stelexis.com",[33,51,65,80,95,110,125,131,142,157,171,186,201],{"facility":34,"status":35,"city":36,"state":37,"zip":38,"country":39,"cosmosGeoPoint":40,"geoPoint":45,"contacts":46},"City of Hope","RECRUITING","Duarte","California","91010","United States",{"type":41,"coordinates":42},"Point",[43,44],-117.97729,34.13945,{"lat":44,"lon":43},[47],{"name":48,"role":29,"phone":49,"phoneExt":11,"email":50},"Shukaib Arslan","626-218-1133","sarslan@coh.org",{"facility":52,"status":35,"city":53,"state":54,"zip":55,"country":39,"cosmosGeoPoint":56,"geoPoint":60,"contacts":61},"Anshutz Cancer Pavilion","Aurora","Colorado","80045",{"type":41,"coordinates":57},[58,59],-104.83192,39.72943,{"lat":59,"lon":58},[62],{"name":63,"role":29,"phone":11,"phoneExt":11,"email":64},"Kara Grau","kara.grau@cuanschutz.edu",{"facility":66,"status":35,"city":67,"state":68,"zip":69,"country":39,"cosmosGeoPoint":70,"geoPoint":74,"contacts":75},"Moffitt Cancer Center","Tampa","Florida","33612",{"type":41,"coordinates":71},[72,73],-82.45843,27.94752,{"lat":73,"lon":72},[76],{"name":77,"role":29,"phone":78,"phoneExt":11,"email":79},"Wes Mungal","813-745-0851","Wesley.Mungal@moffitt.org",{"facility":81,"status":35,"city":82,"state":83,"zip":84,"country":39,"cosmosGeoPoint":85,"geoPoint":89,"contacts":90},"Dana-Farber Cancer Institute","Boston","Massachusetts","02215",{"type":41,"coordinates":86},[87,88],-71.05977,42.35843,{"lat":88,"lon":87},[91],{"name":92,"role":29,"phone":93,"phoneExt":11,"email":94},"Megan Forsyth","857-215-1405","Megan_Forsyth@DFCI.Harvard.edu",{"facility":96,"status":35,"city":97,"state":98,"zip":99,"country":39,"cosmosGeoPoint":100,"geoPoint":104,"contacts":105},"Washington University in St Louis","St Louis","Missouri","63110",{"type":41,"coordinates":101},[102,103],-90.19789,38.62727,{"lat":103,"lon":102},[106],{"name":107,"role":29,"phone":108,"phoneExt":11,"email":109},"Na'kie Coleman-Elhasan","314-454-8708","nakie@wustl.edu",{"facility":111,"status":112,"city":113,"state":113,"zip":114,"country":39,"cosmosGeoPoint":115,"geoPoint":119,"contacts":120},"Memorial Sloan Kettering Cancer Center","NOT_YET_RECRUITING","New York","10065",{"type":41,"coordinates":116},[117,118],-74.00597,40.71427,{"lat":118,"lon":117},[121],{"name":122,"role":29,"phone":123,"phoneExt":11,"email":124},"Anmol Shah","646-608-2813","shaha10@mskcc.org",{"facility":111,"status":35,"city":113,"state":113,"zip":114,"country":39,"cosmosGeoPoint":126,"geoPoint":128,"contacts":129},{"type":41,"coordinates":127},[117,118],{"lat":118,"lon":117},[130],{"name":122,"role":29,"phone":123,"phoneExt":11,"email":124},{"facility":132,"status":35,"city":113,"state":113,"zip":133,"country":39,"cosmosGeoPoint":134,"geoPoint":136,"contacts":137},"Montefiore Medical Center","10466",{"type":41,"coordinates":135},[117,118],{"lat":118,"lon":117},[138],{"name":139,"role":29,"phone":140,"phoneExt":11,"email":141},"Davina Hoban","201-618-4725","davinahoban@montefiore.org",{"facility":143,"status":35,"city":144,"state":145,"zip":146,"country":39,"cosmosGeoPoint":147,"geoPoint":151,"contacts":152},"Cleveland Clinic","Cleveland","Ohio","44106",{"type":41,"coordinates":148},[149,150],-81.69541,41.4995,{"lat":150,"lon":149},[153],{"name":154,"role":29,"phone":155,"phoneExt":11,"email":156},"Ibraheem Al-Aref","216-442-0461","ali3@ccf.org",{"facility":158,"status":35,"city":159,"state":145,"zip":160,"country":39,"cosmosGeoPoint":161,"geoPoint":165,"contacts":166},"Ohio State University","Columbus","43210",{"type":41,"coordinates":162},[163,164],-82.99879,39.96118,{"lat":164,"lon":163},[167],{"name":168,"role":29,"phone":169,"phoneExt":11,"email":170},"Sarah Mayne","614-685-9573","sarah.mayne@osumc.edu",{"facility":172,"status":35,"city":173,"state":174,"zip":175,"country":39,"cosmosGeoPoint":176,"geoPoint":180,"contacts":181},"MD Anderson Cancer Center","Houston","Texas","77054",{"type":41,"coordinates":177},[178,179],-95.36327,29.76328,{"lat":179,"lon":178},[182],{"name":183,"role":29,"phone":184,"phoneExt":11,"email":185},"Meagan Sachs","713-503-1589","msachs@mdanderson.org",{"facility":187,"status":35,"city":188,"state":11,"zip":189,"country":190,"cosmosGeoPoint":191,"geoPoint":195,"contacts":196},"Hospital San Pedro de Alcántara","Cáceres","10003","Spain",{"type":41,"coordinates":192},[193,194],-6.37224,39.47649,{"lat":194,"lon":193},[197],{"name":198,"role":29,"phone":199,"phoneExt":11,"email":200},"Juan Miguel Bergua Burgues","+34 675 699735","jmberguaburg@gmail.com",{"facility":202,"status":35,"city":203,"state":11,"zip":204,"country":190,"cosmosGeoPoint":205,"geoPoint":209,"contacts":210},"Hospital Universitari i Politècnic La Fe","Valencia","46026",{"type":41,"coordinates":206},[207,208],-0.37966,39.47391,{"lat":208,"lon":207},[211],{"name":212,"role":29,"phone":213,"phoneExt":11,"email":214},"Rebeca Rodriguez Veiga","+34 961 245876","rebeca_rodriguez@iislafe.es",{"type":216,"investigatorFullName":11,"investigatorTitle":11,"investigatorAffiliation":11,"oldNameTitle":11,"oldOrganization":11},"SPONSOR","100557103",false,"NCT06533761","Eganelisib as Monotherapy and in Combination With Cytarabine in Relapsed\u002FRefractory AML","A Phase 1b Open-Label Study to Evaluate the Safety and Tolerability of Eganelisib as Monotherapy and in Combination With Cytarabine in Patients With Relapsed\u002FRefractory Acute Myeloid Leukemia","Inclusion Criteria:\n\n* Pathological diagnosis of either: AML according to World Health Organization (WHO) 2022 revised criteria per the local pathology report and with ≥10% bone marrow blasts (acute promyelocytic leukemia is excluded but secondary AML and treatment-related AML can be included); Higher-risk (IPSS-R Intermediate, High or Very High Risk at time of study entry) myelodysplastic syndromes (HR-MDS) according to WHO 2022 revised criteria per the local pathology report and with ≥10% bone marrow blasts.\n* Eastern Cooperative Oncology Group (ECOG) performance status ≤2.\n* Adequate hepatic and renal function measured within 7 days prior to the first dose of eganelisib.\n\nExclusion Criteria:\n\n* Autologous or allogeneic stem cell transplant within 6 months prior to Cycle 1 Day 1.\n* Receiving immunosuppressants (eg, cyclosporin) or systemic steroids (except for steroid use as cortisol replacement therapy in documented adrenal insufficiency).\n* Active fungal disease or uncontrolled infection of any kind; patients receiving antibiotic, antifungal or antiviral treatment must be afebrile and hemodynamically stable for \\>72 hours prior to treatment\n* WBC count \\>25 × 10\\^9\u002FL measured within 7 days prior to the first dose of eganelisib (hydroxyurea is permitted to decrease the WBC count).\n* Presence of a clinically significant non-hematologic toxicity of prior therapy that has not resolved to Grade ≤1 or Baseline, whichever is worst, as determined by NCI CTCAE v 5.0, except alopecia or skin pigmentation. Fatigue and neuropathy must have resolved to Grade ≤2.","ALL","18 Years",{"count":226,"type":227},125,"ESTIMATED","INTERVENTIONAL",[230],"PHASE1","This is a Phase 1b open-label, multicenter, dose-escalation and dose-optimization study designed to evaluate the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD), and anti-tumor efficacy of eganelisib as monotherapy and in combination with cytarabine in patients with relapsed\u002Frefractory (r\u002Fr) acute myeloid leukemia (AML) or r\u002Fr higher-risk myelodysplastic syndromes (HR-MDS).\n\nThe study consists of 2 parts:\n\n* Part 1: Dose Escalation (DE) in both monotherapy and in combination.\n* Part 2: Dose Optimization",[233,234],"AML, Adult","MDS","2025-10-20",{"date":237,"type":238},"2025-10-22","ACTUAL",{"date":240,"type":238},"2025-04-28",{"date":242,"type":227},"2028-03-15",{"name":5,"class":6},13]